左旋咪唑(Levamiosle)原本是一種驅蟲劑，有研究發現其具有抑制卵巢癌細胞生長的效果，我們想了解Levamisole對卵巢癌細胞株SKOV-3與CP70的毒性效果，並且設計一個藥物載體來包覆Levamisole，載體材料為聚乙烯吡咯烷酮(Polyvinylpyrrolidone, PVP)和聚甲基丙烯酸甲酯(Poly(methyl methacrylate), PMMA)，並透過電噴灑的方式來製備粒子與包覆藥物，經由掃描式電子顯微鏡的觀察，粒子的粒徑大小約為1到1.5 µm，將包覆藥物的粒子簡寫為Leva/PVP/PMMA MPs，可以使用兩種方式收集粒子，分別為懸浮液收集和乾式收集，透過水溶實驗發現粒子表面會部分溶於水而產生孔隙，且嘗試在粒子表面改質以嫁接抗體，嫁接後表面抗體濃度為821 µg/mL，而 Leva/PVP/PMMA MPs的藥物包覆量為0.1%，藥物包覆率為20%， freedrug在1小時內釋放50%，而在24小時就釋放達90%的藥量，而Leva/PVP/PMMA MPs釋放速率較freedrug慢，直到5小時才釋放50%，到24小時釋放70%，在細胞實驗方面，5 mM的Levamisole freedrug對卵巢癌細胞株SKOV-3有60%的抑制生長效果，而對卵巢癌細胞株CP70僅能抑制30%的細胞生長，而0.1 g/mL的Leva/PVP/PMMA MPs可以抑制60%的卵巢癌細胞株SKOV-3，在卵巢癌細胞株CP70方面並無顯著的細胞毒性。

Levamisole is a kind of drug which is used to treat worm infections .Recently, there is a new research discovering that Levamisole can inhibit the growth of ovarian cancer cells. We want to study the cell toxicity of Levamisole to ovarian cancer cell lines SKOV-3 & CP70, and design a drug carrier composed of PVP and PMMA. We produced the drug carrier and encapsulated Levamisole by electrospray system. Through the observation of SEM, the particle size is falling between 1.0-1.5 µm. The abbreviation of this drug carrier is Leva/PVP/PMMA MPs. We could collect the particles by two methods including dry collection and suspension collection, and found porosity created on the surface of particles after being soaked in water 20 minutes. The encapsulation efficiency of Leva/PVP/PMMA MPs is 20%, and drug loading content is 0.1%. Freedrug of Levamisole released 50% of drugs in 1 hour and 90% of drugs in one day. Compared to freedrug, the rate of drug release of Leva/PVP/PMMA MP is much slower.It released 50% of drugs after 4 hours and 70% of drugs in one day. 5 mM freedrug of Levamisole reduced 60% cell viability toward SKOV-3 cell lines, and the cell toxicity of Leva/PVP/PMMA MPs is same as freedrug. 0.1 g/mL Leva/PVP/PMMA MPs could reduce 60% cell viability toward SKOV-3 cell lines. On the other hand, 5 mM freedrug of Levamisole could only reduce 30% cell viability toward CP70 cell lines, and 0.1 g/mL Leva/PVP/PMMA MPs didn’t have a significant cell toxicity toward CP70 cell lines.

[1] Ovarian Epithelial, Fallopian Tube, and Primary Peritoneal Cancer Treatment (PDQ®)–Patient Version. National Cancer Institute. 2013-12-06 [2014-07-01].
[2] World Cancer Report 2014. World Health Organization. 2014: Chapter 5.12. ISBN 9283204298.
[3] Piek JM, van Diest PJ, Verheijen RH. Ovarian carcinogenesis: an alternative hypothesis. Adv. Exp. Med. Biol. Advances in Experimental Medicine and Biology. 2008, 622:79-87. ISBN 978-0-387-68966-1. PMID 18546620. doi:10.1007/978-0-387-68969-2_7
[4] Ozols RF, Rubin SC, Thomas G, et al. Epithelial ovarian cancer, in Hoskins WJ,
Perez CA, Young RC (eds): Principles and Practice of Gynecologic Oncology, 2nd ed,chap 32, pp 939-941. Philadelphia, Lippincott Williams & Wilkins, 1997.
[5] NCCN (National Comprehensive Cancer Network) Clinical Practice Guidelines in
Ovarian Cancer - version 1. 2007.
[6] Standards, Options and Recommendations. Clinical practice guidelines for cancer
care from the French National Federation of Cancer (FNCLCC). Ovarian cancer. Bri J
Cancer 2001; 84(Suppl 2):18-23.
[7] Miki Y, Swensen J, Shattuck-Eidens D, Futreal PA, Harshman K, Tavtigian S, Liu Q, Cochran C, Bennett LM, Ding W, et al. A strong candidate for the breast and ovarian cancer susceptibility gene BRCA1. Science, New Series, Vol. 266, No. 5182 (Oct. 7, 1994), pp. 66-71
[8] Shepherd JH. Revised FIGO staging for gynaecological cancer. Br J Obstet
Gynaecol 1989; 96:889-892.
[9] Ovary. In: American Joint Committee on Cancer: AJCC Cancer Staging Manual.
Philadelphia, Pa: Lippincott-Raven Publishers, 5th ed., 1997, pp 201-206.
[10] FIGO staging classifications and clinical practice guidelines in the management ofgynecologic cancers. Int J Gynecol Obstet 2000; 70:209-262.
[11] Standards, Options and Recommendations. Clinical practice guidelines for cancer
care from the French National Federation of Cancer (FNCLCC). Ovarian cancer. Bri J
Cancer 2001; 84(Suppl 2):18-23.
[12] Narod SA, Sun P, Ghadirian P, et al. Tubal ligation and risk of ovarian cancer in
carriers of BRCA1 or BRCA2 mutations: a case-control study. Lancet 2001; 357:
1467-1470.
[13] Haber D. Prophylactic oophorectomy to reduce the risk of ovarian and breast cancer in carriers of BRCA mutations. N Engl J Med 2002; 346:1660-1662.
[14] Muggia FM, Braly PS, Brady MF, et al. Phase III randomized study of cisplatin versus paclitaxel versus cisplatin and paclitaxel in patients with suboptimal stage III or IV ovarian cancer: a gynecologic oncology group study. J Clin Oncol 2000; 18:106-115.
[15]Ozols RF, Bundy BN, Greer BE, et al. Gynecologic Oncology Group. Phase III trial of carboplatin and paclitaxel compared with cisplatin and paclitaxel in patients with optimally resected stage III ovarian cancer: a Gynecologic Oncology Group study. J Clin Oncol. 2003 Sep 1; 21(17):3194-3200.
[16] International Collaborative Ovarian Neoplasm Group. Paclitaxel plus carboplatin
versus standard chemotherapy with either single-agent carboplatin or cyclophosphamide,doxorubicin and cisplatin in women with ovarian cancer: the ICON3 randomised trial. Lancet. 2002 Aug 17; 360(9332):505-515.
[17] Markman M, Hakes T, Reichman B, et al. Ifosfamide and mesna in previously-treated advanced epithelial ovarian cancer: Activity in platinum-resistant disease. J Clin Oncol 1992; 10:243-248.
[18] Vergote I, Himmelmann A, Frankendal B, et al. Hexamethylmelamine as second-line therapy in platinum-resistant ovarian cancer. Gynecol Oncol 1992; 47:282-286.
[19] Bajetta E, Di Leo A, Biganzoli L, et al. Phase II study of vinorelbine in patients with pretreated advanced ovarian cancer: Activity in platinum-resistant disease. J Clin
Oncol 1996; 14:2546-2551.
[20] Lund B, Hansen OP, Theilade K, et al. Phase II study of gemcitabine (2',2' -
difluorodeoxycytidine) in previously treated ovarian cancer patients. J Natl Cancer
Inst 1994; 86:1530-1533.
[21] Rose PG, Blessing JA, Mayer AR, et al. Prolonged oral etoposide as second line
therapy for platinum resistant (PLATR) and platinum sensitive (PLATS) ovarian carcinoma: A Gynecologic Oncology Group study. Proc Am Soc Clin Oncol 1992;
15:282.
[22] Muggia FM, Hainsworth JD, Jeffers S, et al. Phase II study of liposomal doxorubicin in refractory ovarian cancer: Antitumor activity and toxicity modification by encapsulation. J Clin Oncol 1997; 15:987-993.
[23] ten Bokkel Huinink W, Gore M, Carmichael J, et al. Topotecan vs paclitaxel for the treatment of recurrent epithelial ovarian cancer. J Clin Oncol 1997; 15:2183-2193.
[24] Gordon AN, Fleagle JT, Guthrie D, Parkin DE, Gore ME, Lacave AJ. Recurrent
epithelial ovarian carcinoma: a randomized phase III study of pegylated liposomal
doxorubicin versus topotecan. J Clin Oncol 2001; 19:3312-3322.
[25] Gordon AN, Tonda M, Sun S, Rackoff W; Doxil Study 30-49 Investigators. Long-term survival advantage for women treated with pegylated liposomal doxorubicin compared with topotecan in a phase 3 randomized study of recurrent and refractory epithelial ovarian cancer. Gynecol Oncol 2004; 95:1-8.
[26] Brayfield, A . Aspirin. Martindale: The Complete Drug Reference. Pharmaceutical Press. 14 January 2014 [3 April 2014].
[27] Lewis, H. D.; Davis, J. W.; Archibald, D. G.; Steinke, W. E.; Smitherman, T. C.; Doherty Je, J. E.; Schnaper, H. W.; Lewinter, M. M.; Linares, E.; Pouget, J. M.; Sabharwal, S. C.; Chesler, E.; Demots, H. Protective Effects of Aspirin against Acute Myocardial Infarction and Death in Men with Unstable Angina. New England Journal of Medicine. 1983, 309 (7):396–403. PMID 6135989. doi:10.1056/NEJM198308183090703
[28] Julian, D G; D A Chamberlain; S J Pocock. A comparison of aspirin and anticoagulation following thrombolysis for myocardial infarction (the AFTER study): a multicentre unblinded randomised clinical trial. BMJ (British Medical Journal). 24 September 1996, 313 (7070): 1429–1431. PMC 2353012. PMID 8973228. doi:10.1136/bmj.313.7070.1429.
[29] Krumholz, H. M.; Radford, M. J.; Ellerbeck, E. F.; Hennen, J.; Meehan, T. P.; Petrillo, M.; Wang, Y.; Kresowik, T. F.; Jencks, S. F. Aspirin in the treatment of acute myocardial infarction in elderly Medicare beneficiaries. Patterns of use and outcomes. Circulation. 1995, 92 (10): 2841–2847. PMID 7586250. doi:10.1161/01.CIR.92.10.2841.
[30] Algra, Annemijn M; Rothwell, Peter M. Effects of regular aspirin on long-term cancer incidence and metastasis: A systematic comparison of evidence from observational studies versus randomised trials. The Lancet Oncology. 2012, 13 (5): 518–27. PMID 22440112. doi:10.1016/S1470-2045(12)70112-2.
[31] Rothwell, Peter M; Wilson, Michelle; Price, Jacqueline F; Belch, Jill FF; Meade, Tom W; Mehta, Ziyah. Effect of daily aspirin on risk of cancer metastasis: A study of incident cancers during randomised controlled trials. The Lancet. 2012, 379 (9826): 1591–1601. PMID 22440947. doi:10.1016/S0140-6736(12)60209-8.
[32] Rothwell, Peter M; Price, Jacqueline F; Fowkes, F Gerald R; Zanchetti, Alberto; Roncaglioni, Maria Carla; Tognoni, Gianni; Lee, Robert; Belch, Jill FF; Wilson, Michelle; 等. Short-term effects of daily aspirin on cancer incidence, mortality, and non-vascular death: Analysis of the time course of risks and benefits in 51 randomised controlled trials. The Lancet. 2012, 379 (9826): 1602–1612. doi:10.1016/S0140-6736(11)61720-0.
[33] Keiser, J; Utzinger, J (23 April 2008). "Efficacy of current drugs against soil-transmitted helminth infections: systematic review and meta-analysis.". JAMA. 299 (16): 1937–48. PMID 18430913. doi:10.1001/jama.299.16.1937.
[34] Sanford, Shari (2007). "Levamisole Hydrochloride: Its application and usage in freshwater aquariums". Loaches Online. Retrieved 2009-02-27.
[35] WHO Model Formulary 2008 . World Health Organization. 2009. pp. 86, 590. ISBN 9789241547659.
[36] "WHO Model List of Essential Medicines (19th List)" . World Health Organization. April 2015. Retrieved 8 December2016.
[37] Kouassi, E (1986). "Novel assay and pharmacokinetics of levamisole and p-hydroxylevamisole in human plasma and urine". Biopharmaceutics & Drug Disposition. 7 (1): 71–89. PMID 3754161. doi:10.1002/bdd.2510070110.
[38] Luyckx, M (1982). "Pharmacokinetics of levamisole in healthy subjects and cancer patients". European Journal of Drug Metabolism and Pharmacokinetics. 7 (4): 247–54. PMID 7166176. doi:10.1007/bf03189626.
[39] Crispian Scully, M.D., Ph.D., M.D.S. "Aphthous Ulceration"N Engl J Med 2006; 355:165-172July 13, 2006DOI: 10.1056/NEJMcp054630
[40] Barrons RW "Treatment strategies for recurrent oral aphthous ulcers. "Am J Health Syst Pharm. 2001 Jan 1;58(1):41-50; quiz 51-3.
[41] Charles G. Moertel, MD; Thomas R. Fleming, PhD; John S. Macdonald, MD; Daniel G. Haller, MD; John A. Laurie, MD; Catherine M. Tangen, MS; James S. Ungerleider, MD; William A. Emerson, MD; Douglass C. Tormey, MD, PhD; John H. Glick, MD; Michael H. Veeder, MD; James A. Mailliard, MD(1995)"Fluorouracil plus Levamisole as Effective Adjuvant Therapy after Resection of Stage III Colon Carcinoma: A Final Report"ANNALS OF INTERNAL MEDICINE,122(5),p321-326
[42] Kuei-Chun Liu, Yi-Te Yo, Rui-Lan Huang, Yu-Chi Wang, Yu-Ping Liao, Tien-Shuo Huang, Tai-Kuang Chao, Chi-Kang Lin, Shao-Ju Weng, Kuo-Hsing Ma, Cheng-Chang Chang, Mu-Hsien Yu, Hung-Cheng Lai(2014) "Ovarian cancer stem-like cells with induced translineage-differentiation capacity and are suppressed by alkaline phosphatase inhibitor"Oncotarget. 2014; 4:2366-2382.
[43] Targeted therapy, National Cancer Institute,August 15 2014
[44] George D. Demetri, M.D., Margaret von Mehren, M.D., Charles D. Blanke, M.D., Annick D. Van den Abbeele, M.D., Burton Eisenberg, M.D., Peter J. Roberts, M.D., Michael C. Heinrich, M.D., David A. Tuveson, M.D., Ph.D., Samuel Singer, M.D., Milos Janicek, M.D., Ph.D., Jonathan A. Fletcher, M.D., Stuart G. Silverman, M.D., Sandra L. Silberman, M.D., Ph.D., Renaud Capdeville, M.D., Beate Kiese, M.Sc., Bin Peng, M.D., Ph.D., Sasa Dimitrijevic, Ph.D., Brian J. Druker, M.D., Christopher Corless, M.D., Christopher D.M. Fletcher, M.D., and Heikki Joensuu, M.D.(2002) "Efficacy and Safety of Imatinib Mesylate in Advanced Gastrointestinal Stromal Tumors",N Engl J Med 2002; 347:472-480,August 15, 2002,DOI: 10.1056/NEJMoa020461
[45] Brian J. Druker, M.D., Moshe Talpaz, M.D., Debra J. Resta, R.N., Bin Peng, Ph.D., Elisabeth Buchdunger, Ph.D., John M. Ford, M.D., Nicholas B. Lydon, Ph.D., Hagop Kantarjian, M.D., Renaud Capdeville, M.D., Sayuri Ohno-Jones, B.S., and Charles L. Sawyers, M.D.(2001) " Efficacy and Safety of a Specific Inhibitor of the Bcr-Abl Tyrosine Kinase in Chronic Myeloid Leukemia." N Engl J Med 2001; 344:1031-1037,April 5, 2001,DOI: 10.1056/NEJM200104053441401
[46] Druker BJ, Sawyers CL, Kantarjian H, Resta DJ, Reese SF, Ford JM, Capdeville R, Talpaz M. "Activity of a specific inhibitor of the BCR-ABL tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with the Philadelphia chromosome." N Engl J Med 2001 Jul 19;345(3):232.
[47] Naumann, RW ; Coleman, RL ; Burger, RA ( ; Sausville, EA ; Kutarska, E ; Ghamande, SA ; Gabrail, NY ; DePasquale, SE ; Nowara, E ; Gilbert, L ; Gersh, RH ; Teneriello, MG ; Harb, WA; Konstantinopoulos, PA ; Penson, RT ; Symanowski, JT ; Lovejoy, CD ; Leaman, CP ; Morgenstern, DE ; Messmann, RA(2013)"PRECEDENT: A Randomized Phase II Trial Comparing Vintafolide (EC145) and Pegylated Liposomal Doxorubicin (PLD) in Combination Versus PLD Alone in Patients With Platinum-Resistant Ovarian Cancer"JOURNAL OF CLINICAL ONCOLOGY,31(35), DOI: 10.1200/JCO.2013.49.7685
[48] Napoleone Ferrara , Kenneth J. Hillan, William Novotny(2005) "Bevacizumab (Avastin), a humanized anti-VEGF monoclonal antibody for cancer therapy " Biochemical and Biophysical Research Communications,Volume 333, Issue 2, 29 July 2005, Pages 328–335
[49] Tanja Hakkarainen, Akseli Hemminki, Alexander V. Pereboev, Shannon D. Barker, Clement K. Asiedu, Theresa V. Strong, Anna Kanerva, Jarmo Wahlfors, and David T. Curiel " CD40 Is Expressed on Ovarian Cancer Cells and Can Be Utilized for Targeting Adenoviruses "Advances in Brief, Vol. 9, 619–624, February 2003
[50] G. FERRANDINA, G. BONANNO, L. PIERELLIz, A. PERILLO, A. PROCOLI, A. MARIOTTI, M. CORALLO, E. MARTINELLI, S. RUTELLA, A. PAGLIA, G. ZANNONIk, S. MANCUSO & G. SCAMBIA"Expression of CD133-1 and CD133-2 in ovarian cancer"Int J Gynecol Cancer 2008, 18, 506–514
[51]JingZhang, XiaoqingGuo, DooYoungChang, DanielG.Rosen, ImeldaMercado-Uribe,andJinsong Liu"CD133 expression associated with poor prognosis in ovarian cancer"Mod Pathol. 2012 Mar; 25(3): 10.1038/modpathol.2011.170.
[52] Matsumura Y, Maeda H. A new concept for macromolecular therapeutics in cancer chemotherapy: mechanism of tumoritropic accumulation of proteins and the antitumor agent smancs. Cancer Research. December 1986, 46 (12 Pt 1): 6387–92. PMID 2946403.
[53] Makadia, HK (Makadia, Hirenkumar K.); Siegel, SJ (Siegel, Steven J.) Poly Lactic-co-Glycolic Acid (PLGA) as Biodegradable Controlled Drug Delivery Carrier, Polymers 2011, 3(3), 1377-1397; doi:10.3390/polym3031377
[54] Park, EK ; Lee, SB ; Lee, YM . Preparation and characterization of methoxy poly(ethylene glycol)/poly(epsilon-caprolactone) amphiphilic block copolymeric nanospheres for tumor-specific folate-mediated targeting of anticancer drugs, Biomaterials,Volume 26, Issue 9, March 2005, Pages 1053-1061
[55] Dhruba Jyoti Bharali, Sanjeeb Kumar Sahoo,1 Subho Mozumdar, and Amarnath Maitra, Cross-linked polyvinylpyrrolidone nanoparticles: a potential carrier for
hydrophilic drugs, Journal of Colloid and Interface Science 258 (2003) 415–423
[56] Andrey N. Kuskov • Anna A. Voskresenskaya •Anastasiya V. Goryachaya • Alexander A. Artyukhov •Mikhail I. Shtilman • Aristidis M. Tsatsakis.Preparation and characterization of amphiphilic poly-N-vinylpyrrolidone nanoparticles containing indomethacin, J Mater Sci: Mater Med (2010) 21:1521–1530,DOI 10.1007/s10856-010-4029-1
[57] Yang Cao, Bochu Wang,* Yazhou Wang and Deshuai Lou, Polymer-controlled core–shell nanoparticles: a novel strategy for sequential drug release, RSC Adv., 2014, 4, 30430
[58] Eliav Shaked, Yoav Shani, Meital Zilberman, Mickey Scheinowitz. Poly(methyl methacrylate) particles for local drug delivery using shock
wave lithotripsy: In vitro proof of concept experiment, J Biomed Mater Res B Appl Biomater. 2015 Aug;103(6):1228-37. doi: 10.1002/jbm.b.33301
[59] M. Sairam, V. Ramesh Babu, K. S. V. Krishna Rao, T. M. Aminabhavi. Poly(methylmethacrylate)-Poly(vinyl pyrrolidone) Microspheres as Drug Delivery Systems: Indomethacin/ Cefadroxil Loading and In Vitro Release Study,Journal of Applied Polymer Science, Volume 104, Issue 3 5 May 2007 Pages 1860–1865
[60] Taylor, G. Disintegration of Water Drops in an Electric Field. Proceedings of the Royal Society A. 1964, 280 (1382): 383. JSTOR 2415876. doi:10.1098/rspa.1964.0151.
[61] Taylor, G. Electrically Driven Jets. Proceedings of the Royal Society A. 1969, 313 (1515): 453. JSTOR 2416488. doi:10.1098/rspa.1969.0205.
[62] Salata, O.V. (2005). "Tools of nanotechnology: Electrospray". Current Nanoscience. 1: 25–33. doi:10.2174/1573413052953192.
[63]Doshi, J. and Reneker, D. H. Electrospinning process and applications of electrospun fibers. Journal of Electrostatics. 1995, 35 (2–3): 151. doi:10.1016/0304-3886(95)00041-8
[64] Norman Wolmark, Howard Rockette, Eleftherios Mamounas, Judy Jones, Sam Wieand, D.L. Wickerham, Harry D. Bear, James N. Atkins, Nikolay V. Dimitrov, Andrew G. Glass, Edwin R. Fisher, Bernard Fisher. Clinical trial to assess the relative efficacy of fluorouracil and leucovorin, fluorouracil and levamisole, and fluorouracil, leucovorin, and levamisole in patients with Dukes' B and C carcinoma of the colon: Results from national surgical adjuvant breast and bowel project C-04, JOURNAL OF CLINICAL ONCOLOGY, 17, no. 11 (November 1999) 3553-3559. DOI: 10.1200/JCO.1999.17.11.3553
[65] K.MGallagher. O.ICorrigan. Mechanistic aspects of the release of levamisole hydrochloride from biodegradable polymers. Journal of Controlled Release
Volume 69, Issue 2, 3 November 2000, Pages 261-272
[66] Fernández de la Mora, J. & Loscertales, I. G. (1994). "The current emitted by highly conductive Taylor cones.". Journal of Fluid Mechanics. 260: 155–184. Bibcode:1994JFM...260..155D. doi:10.1017/S0022112094003472
[67] Yun Liu, HuixiangWang, Jingyu Huang, Jie Yang, Baohong Liu, Pengyuan Yang. Microchip-based ELISA strategy for the detection of low-level disease
biomarker in serum. Analytica Chimica Acta 650 (2009) 77–82